Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879403 | 0.87 | GAA (0.56) | PARP1GAACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13879575 | 0.82 | KDM4E (0.42) | PARP1GAACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13879558 | 0.82 | NPSR1 (0.46) | NPSR1PARP1GAACYP1A2CYP3A4 | |
| SCHEMBL13879495 | 0.78 | GAA (0.45) | NPSR1TNFGAACYP1A2CYP3A4 | |
| SCHEMBL13879432 | 0.78 | RGS4 (0.45) | NPSR1TNFPARP1GAACYP1A2 | |
| SCHEMBL10387768 | 0.76 | PARP1 (0.59) | NPSR1PARP1GAACYP1A2CYP3A4 | |
| SCHEMBL13879459 | 0.76 | ALDH1A1 (0.61) | GAACYP1A2CYP3A4CYP2C19POLB | |
| SCHEMBL13879370 | 0.74 | NPSR1 (0.45) | NPSR1TNFPARP1GAACYP1A2 | |
| SCHEMBL13879477 | 0.73 | RIPK1 (0.37) | NPSR1TNFROCK2MGLL | |
| SCHEMBL13879413 | 0.73 | MGLL (0.41) | CYP1A2CYP3A4CYP2C19MAPK1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | NPSR1 4621/4885TNF 1854/4885PARP1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.